• Je něco špatně v tomto záznamu ?

Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis

R. Atreya, S. Bloom, F. Scaldaferri, V. Gerardi, C. Admyre, Å. Karlsson, T. Knittel, J. Kowalski, M. Lukas, R. Löfberg, S. Nancey, R. Petryka, G. Rydzewska, R. Schnabel, U. Seidler, MF. Neurath, C. Hawkey,

. 2016 ; 10 (11) : 1294-1302. [pub] 20160520

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023573

BACKGROUND AND AIMS: Toll-like receptors [TLRs] are potential drug targets for immunomodulation. We determined the safety and efficacy of the TLR-9 agonist DNA-based immunomodulatory sequence 0150 [DIMS0150] in ulcerative colitis [UC] patients refractory to standard therapy. METHODS: In this randomized, double-blind, placebo-controlled trial, 131 patients with moderate-to-severe active UC were randomized to receive two single doses of the oligonucleotide DIMS0150 [30 mg] or placebo administered topically during lower GI endoscopy at baseline and Week 4. The primary endpoint was clinical remission, defined as Clinical Activity Index [CAI] ≤4, at Week 12. Secondary endpoints included mucosal healing and symptomatic remission of key patient-reported outcomes [absence of blood in stool and weekly stool frequency <35]. RESULTS: There was no statistical significant difference between the groups in the induction of clinical remission at Week 12, with 44.4% in the DIMS0150 group vs. 46.5% in the placebo group. However, the proportion of patients who achieved symptomatic remission was 32.1% in the DIMS0150 group vs. 14.0% in the placebo group at Week 4 [p = 0.020], and 44.4% vs. 27.9% at Week 8 [p = 0.061]. More patients on DIMS0150 compared with those on placebo had mucosal healing [34.6% vs. 18.6%; p = 0.09] and histological improvement regarding the Geboes score [30.9% vs. 9.3%; p = 0.0073] at Week 4. Significantly more patients on DIMS0150 were in clinical remission with mucosal healing at Week 4: 21% vs. 4.7% in the placebo group [p = 0.02]. DIMS0150 was well tolerated, and no safety signals compared with placebo were evident. CONCLUSIONS: Therapy with the topically applied TLR-9 agonist DIMS0150 is a promising and well-tolerated novel therapeutic option for treatment-refractory, chronic active UC patients, warranting further clinical trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023573
003      
CZ-PrNML
005      
20170906121437.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjw103 $2 doi
035    __
$a (PubMed)27208386
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Atreya, Raja $u Medical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. $7 gn_A_00009819
245    10
$a Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis / $c R. Atreya, S. Bloom, F. Scaldaferri, V. Gerardi, C. Admyre, Å. Karlsson, T. Knittel, J. Kowalski, M. Lukas, R. Löfberg, S. Nancey, R. Petryka, G. Rydzewska, R. Schnabel, U. Seidler, MF. Neurath, C. Hawkey,
520    9_
$a BACKGROUND AND AIMS: Toll-like receptors [TLRs] are potential drug targets for immunomodulation. We determined the safety and efficacy of the TLR-9 agonist DNA-based immunomodulatory sequence 0150 [DIMS0150] in ulcerative colitis [UC] patients refractory to standard therapy. METHODS: In this randomized, double-blind, placebo-controlled trial, 131 patients with moderate-to-severe active UC were randomized to receive two single doses of the oligonucleotide DIMS0150 [30 mg] or placebo administered topically during lower GI endoscopy at baseline and Week 4. The primary endpoint was clinical remission, defined as Clinical Activity Index [CAI] ≤4, at Week 12. Secondary endpoints included mucosal healing and symptomatic remission of key patient-reported outcomes [absence of blood in stool and weekly stool frequency <35]. RESULTS: There was no statistical significant difference between the groups in the induction of clinical remission at Week 12, with 44.4% in the DIMS0150 group vs. 46.5% in the placebo group. However, the proportion of patients who achieved symptomatic remission was 32.1% in the DIMS0150 group vs. 14.0% in the placebo group at Week 4 [p = 0.020], and 44.4% vs. 27.9% at Week 8 [p = 0.061]. More patients on DIMS0150 compared with those on placebo had mucosal healing [34.6% vs. 18.6%; p = 0.09] and histological improvement regarding the Geboes score [30.9% vs. 9.3%; p = 0.0073] at Week 4. Significantly more patients on DIMS0150 were in clinical remission with mucosal healing at Week 4: 21% vs. 4.7% in the placebo group [p = 0.02]. DIMS0150 was well tolerated, and no safety signals compared with placebo were evident. CONCLUSIONS: Therapy with the topically applied TLR-9 agonist DIMS0150 is a promising and well-tolerated novel therapeutic option for treatment-refractory, chronic active UC patients, warranting further clinical trials.
650    _2
$a aplikace lokální $7 D000287
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ulcerózní kolitida $x farmakoterapie $7 D003093
650    _2
$a kolon $x účinky léků $7 D003106
650    _2
$a DNA $x aplikace a dávkování $x terapeutické užití $7 D004247
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a endoskopie $x metody $7 D004724
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunologické faktory $x aplikace a dávkování $x terapeutické užití $7 D007155
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a toll-like receptor 9 $x agonisté $7 D051217
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Bloom, Stuart $u Gastroenterology, University College London Hospital, London, UK.
700    1_
$a Scaldaferri, Franco $u Internal Medicine Department/Gastroenterology Division, Catholic University of Rome, Rome, Italy.
700    1_
$a Gerardi, Viviana $u Internal Medicine Department/Gastroenterology Division, Catholic University of Rome, Rome, Italy.
700    1_
$a Admyre, Charlotte $u InDex Pharmaceuticals, Tomtebodavägen 23A, 171 77 Stockholm, Sweden. $7 gn_A_00001865
700    1_
$a Karlsson, Åsa $u InDex Pharmaceuticals, Tomtebodavägen 23A, 171 77 Stockholm, Sweden.
700    1_
$a Knittel, Thomas $u InDex Pharmaceuticals, Tomtebodavägen 23A, 171 77 Stockholm, Sweden.
700    1_
$a Kowalski, Jan $u JK Biostatistics AB, Stockholm, Sweden.
700    1_
$a Lukas, Milan $u Clinical Centre Isacre Lighthouse, IBD Clinical and Research Centre, Prague, Czech Republic.
700    1_
$a Löfberg, Robert $u Stockholm Gastro Center, Sophiahemmet, Stockholm, Sweden. Department of Medicine, Karolinska Institutet, Solna, Sweden.
700    1_
$a Nancey, Stephane $u Gastroenterology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France.
700    1_
$a Petryka, Robert $u NZOZ Vivamed, Warsaw, Poland.
700    1_
$a Rydzewska, Grazyna $u Central Clinical Hospital Ministry of Interior in Warsaw, Warsaw, Poland. Jan Kochanowski University, Kielce, Poland.
700    1_
$a Schnabel, Robert $u Pannonia Maganorvosi Centrum, Budapest, Hungary.
700    1_
$a Seidler, Ursula $u Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
700    1_
$a Neurath, Markus F $u Medical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
700    1_
$a Hawkey, Christopher $u Department of Gastroenterology, Nottingham Digestive Diseases Centre, Nottingham University Hospitals, Nottingham, UK cj.hawkey@nottingham.ac.uk.
773    0_
$w MED00166945 $t Journal of Crohn's & colitis $x 1876-4479 $g Roč. 10, č. 11 (2016), s. 1294-1302
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27208386 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170906122035 $b ABA008
999    __
$a ok $b bmc $g 1239254 $s 984486
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 10 $c 11 $d 1294-1302 $e 20160520 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace